Viaderma, Inc. Receives Positive Results on Phase I Testing in Canada with its Proprietary THC Delivery and Moves to Phase II Trials and Development of New Products with its MMJ Technologies
May 15, 2017 at 08:59 am EDT
Share
ViaDerma, Inc. announced that the company has completed Phase I testing under patents pending for delivering medical and recreational cannabinoids to the body. The testing was performed in British Columbia, Canada with THC and has proven very successful. The Company plans to conduct medical research and clinical trials to develop Cannabinoids-based pharmaceuticals and treatments for conditions including, but not limited to, psoriasis, fibromyalgia, PTSD, Depression, Anxiety and migraines. The Company will also be pursuing the "Recreational Market" in Canada with expansion plans into the USA once the proper legal standards are addressed. ViaDerma will be begin developing unique delivery systems for the effective delivery and dosage of recreational and medical cannabinoids and plans to start a grass roots product for both THC and non-THC Cannabinoids, both in a patch form, roll on and spray. The plans include distribution in every dispensary across Canada to start with, and add a website for global distribution. The company's success of its first round of testing is compelling and the company plans to start continued Clinical Trials to ensure that the delivery system meets medical standards. The idea is to continue and expand testing to include pure Cannabinoid isolates, including pure THC oil, to ensure that developed products will be accepted by the medical community to treat illness as well as providing the recreational market with a more favorable alternative to smoking or ingesting.
ViaDerma, Inc. is a specialty pharmaceutical company engaged in bringing new products to market and licensing its transdermal drug delivery technology solutions. The Companyâs lead product is a topical antibiotic, which is focused on being sold under the brand name Vitastem. In addition to licensing its proprietary transdermal technologies, its lead product, Vitastem, is available for treating multiple skin conditions and ailments. The Company also has products in development in fields, such as anti-aging skin care, pain management, hair-loss, and toenail fungus. The products are based on a delivery system technology that allows for rapid mass transfer of the pharmaceutical active ingredient across the skin and into the body to provide immediate localized therapy. The Companyâs products are sold to local medical practitioners and patients in clinics primarily in the Los Angeles, California area. The Companyâs subsidiary is ViaDerma, II Inc.
Viaderma, Inc. Receives Positive Results on Phase I Testing in Canada with its Proprietary THC Delivery and Moves to Phase II Trials and Development of New Products with its MMJ Technologies
VIADERMA, INC. 
